Oncology

Serum, Cell-Free, HPV-Human DNA Junction Detection and HPV Typing for Predicting and Monitoring Cervical Cancer Recurrence

1. Anne Van Arsdale
2. Olga Mescheryakova
3. Sonia Gallego
4. Elaine C Maggi
5. Bryan Harmon
6. Dennis YS Kuo
7. Koenraad Van Doorslaer
8. Mark H Einstein
9. Brian J Haas
10. Cristina Montagna
11. Jack Lenz

• Curated by eLife

  eLife Assessment

  This is a valuable study that suggests that HPV-human DNA junctions can be identified from cfDNA in women with cervical cancer and that detection of these junctions is indicative of recurrence. The evidence supporting the conclusions is incomplete, in part because the numbers of reads identifying breakpoints in tumor samples or in circulating cell-free serum samples are not provided. More quantitative analysis will be required to confirm that the breakpoints represented in cell-free DNA can be used as a surrogate to monitor the recurrence of cervical cancer cells, and additional patient studies would also be needed to strengthen the study. This work will be of interest to those who study and treat cervical cancer as well as other HPV-related malignancies.

Reviewed by eLife

Early Diagnosis and Prognostic Prediction of Colorectal Cancer through Plasma Methylation Regions

1. Lingqin Zhu
2. Lang Yang
3. Fangli Men
4. Jianwei Yu
5. Shuyang Sun
6. Chenguang Li
7. Xianzong Ma
8. Junfeng Xu
9. Yangjie Li
10. Ju Tian
11. Xin Wang
12. Hui Xie
13. Qian Kang
14. Linghui Duan
15. Xiang Yi
16. Wei Guo
17. Xueqing Gong
18. Ni Guo
19. Youyong Lu
20. Joseph Leung
21. Yuqi He
22. Jianqiu Sheng

• Curated by eLife

  eLife Assessment

  This study presents an important finding that has identified 27 differentially methylated regions as a signature for non-invasive early cancer detection and predicting prognosis for colorectal cancer. The findings demonstrate promising clinical potential, particularly for improving cancer screening and patient monitoring. In general, the evidence supporting the claims of the authors is solid. A larger sample size will be key to further improving this work in the future. The work will be of interest to researchers interested in cancer diagnosis or colorectal cancer monitoring.

Reviewed by eLife

Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for Recurrent Glioblastoma: An Augmented Meta-analysis of Phase 1 Clinical Trials

1. Ahmed Y. Azzam
2. Mahmoud M. Morsy
3. Mohammed A. Azab
4. Osman Elamin
5. Adam Elswedy
6. Omar S. Ahmed
7. Mahmoud Nassar
8. Ahmed Saad Al Zomia
9. Adham A. Mohamed
10. Oday Atallah
11. Ahmed Alamoud
12. Hammam A. Alotaibi
13. Hana J. Abukhadijah
14. Abdulqadir J Nashwan

Reviewed by PREreview

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

1. Changjun Wang
2. Yan Lin
3. Ying Xu
4. Feng Mao
5. Jinghong Guan
6. Xuejing Wang
7. Yanna Zhang
8. Xiaohui Zhang
9. Songjie Shen
10. Ying Zhong
11. Bo Pan
12. Li Peng
13. Xin Huang
14. Xi Cao
15. Ru Yao
16. Xintong Zhou
17. Zecheng He
18. Yuhan Liu
19. Jie Lang
20. Chenggang Li
21. Yidong Zhou
22. Qiang Sun

• Curated by eLife

  eLife assessment

  This study presents a useful finding for the prevention of diarrhea with loperamide in patients with early HER2-positive breast cancer treated with nab-paclitaxel in combination with pyrotinib. The evidence supporting the claims of the authors is somewhat incomplete. The enrollment of patients as a control group who have not received prophylactic treatment for diarrhea would have strengthened the study, and the addition of double-blinding for the assessment of treatment may be necessary. The work will be of interest to scientists working in the field of clinical breast cancer treatment.

Reviewed by eLife